| Oregon Regeneration Stem Cell Medical Center, Llc | |
|
29781 Sw Town Center Loop, Wilsonville, OR 97070 | |
| (971) 533-6636 | |
| (740) 450-2494 |
| Full Name | Oregon Regeneration Stem Cell Medical Center, Llc |
|---|---|
| Type | Facility |
| Speciality | Advanced Practice Midwife |
| Location | 29781 Sw Town Center Loop, Wilsonville, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275027393 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | (* (Not Available)) | Secondary |
| 367A00000X | Advanced Practice Midwife | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Oregon Regeneration Stem Cell Medical Center, Llc 29781 Sw Town Center Loop, Wilsonville, OR 97070 Ph: (971) 313-4195 | Oregon Regeneration Stem Cell Medical Center, Llc 29781 Sw Town Center Loop, Wilsonville, OR 97070 Ph: (971) 533-6636 |
News Archive
Seattle Children's, with participating members Children's National Health System, BC Children's Hospital and Children's Hospital Los Angeles, has launched CureWorks, an international collaborative of leading academic children's hospitals determined to accelerate the development of immunotherapy treatments for childhood cancer.
An infant's scores on the so-called Apgar scale can predict the risk of a later diagnosis of cerebral palsy or epilepsy. The risk rises with decreasing Apgar score, but even slightly lowered scores can be linked to a higher risk of these diagnoses, according to an extensive observational study by researchers at Karolinska Institutet in Sweden published in the esteemed journal The BMJ.
The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis.
Following encouraging results from Ocular Therapeutix's travoprost punctum plug feasibility study, the company is now entering a pilot Phase II clinical trial to examine a two-month sustained release drug (OTX-TP2) for the treatment of ocular hypertension and glaucoma.
Analysis from business intelligence provider GBI Research - Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation - states that while currently-available drugs aim to manage the frequency and severity of symptoms associated with COPD, none have been shown to modify long-term disease progression.
› Verified 2 days ago